B
Bullisch
Bullisch · 25%PYPD
$4.99
Szenariopreis
$5.670
-0.146 (-2.58%)Zum Schluss
Loading chart…
- Hoch
- 5.930
- Eröffnung
- 5.820
- Volumengewichteter Durchschnittskurs
- 5.65
- Volumen
- 242.04K
- Marktkap.
- 20.15M
- Tief
- 5.360
- Umsatz
- 1.37M
- EV/EBITDA, TTM
- 0.00
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
KI-Analyse of PolyPid Ltd (PYPD)
KaufenPolyPid Ltd is a good buy right now, with a current price of $5.42 and a strong analyst price target of $10 from Oppenheimer, indicating a potential upside of 84%. The company has received FDA priority review for its product D-PLEX100, which could significantly enhance its market position and revenue streams. Additionally, the stock has shown a year-to-date change of +24.60%, reflecting positive momentum. However, the main risk is the ongoing net losses, with a reported loss of $7.8 million in Q2 2026, which investors should monitor closely.
Bewertungskennzahlen
Das aktuelle erwartete KGV von PolyPid Ltd (PYPD) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -1.47.
Alphio-AI-Kursszenarien für PYPD
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Event-Zeitleiste
News
6.010-27CNBCMajor Wall Street Rating Updates
8.510-15NewsfilterPolyPid Unveils 'PolyPid 2030' Long-Term Strategy
9.508-19NASDAQ.COMPolyPid Reports Q2 Loss Reduction Amid Strategic Partnerships
9.007-29seekingalphaPolyPid Receives FDA Priority Review for D-PLEX100
9.007-29NASDAQ.COMPolyPid's D-PLEX100 Receives FDA Priority Review
PYPD FAQ – beantwortet von Alphio AI
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).
PolyPid Ltd is a good buy right now, with a current price of $5.42 and a strong analyst price target of $10 from Oppenheimer, indicating a potential upside of 84%. The company has received FDA priority review for its product D-PLEX100, which could significantly enhance its market position and revenue streams. Additionally, the stock has shown a year-to-date change of +24.60%, reflecting positive momentum. However, the main risk is the ongoing net losses, with a reported loss of $7.8 million in Q2 2026, which investors should monitor closely.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenÄhnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.